SureTrader
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 2/12/2016 4:57:12 PM - Followers: 743 - Board type: Free - Posts Today: 58

 

(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2 ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 

 
                                                                                      
 

 


 

PRESS RELEASES & NEWS ARTICLES

Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
February 10, 2016

Amarantus to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 9, 2016

Burn Care 3.0: Tissue-Engineered Skin is Regenerative Medicine in Action
February 8, 2016
Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

February 5, 2016
Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
February 3, 2016 
Amarantus Announces Issuance of Chinese Patent Covering Use of MANF for the Treatment of Parkinson's Disease

Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF
January 29, 2016
Amarantus Announces $1M Investment
January 27, 2016
Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics

January 19, 2016
Amarantus to Present at ICV Sonoma Event
January 15, 2016
Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
January 11, 2016
Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
DECEMBER 29, 2015
Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
DECEMBER 22, 2015
More News



Bio-engineering skin to treat severe burns
 
 

   Videos

 


 
SNNLive with Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS) - December 2015


 

ESS Patients: Dr. Ahrenholz Interview Part 1 
 

ESS vs the Competition: Dr. Ahrenholz Interview Part 2

The Need for ESS: Dr. Ahrenholz Interview Part 3
 

 Predicting Alzheimer's before it      starts Published on Apr. 8, 2015
 SNNLive - Amarantus BioScience
Holdings, Inc. - 
Dec. 12, 2014

Developing an Accurate Test for Multiple Sclerosis - Mar. 5, 2014
 
 
                                                                                                                  
 
 
    
       
 


                                                               Contact Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111

 

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland












 

info@amarantus.com
pr@amarantus.com


Phone: (415) 688-4484
Fax: (408) 852-4427


Gerald's email address
Gerald@amarantus.com



IR Calendar 






 

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475

ir@amarantus.com


 

TRANSFER AGENT

VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com
www.VStockTransfer.com

 

 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.
 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
                                                                            


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Various Development Advancements for Targeted Treatment Therapies for Rare Diseases & Disorders Lead to Newest Orphan Drug 02/10/2016 08:45:00 AM
AMBS News: Current Report Filing (8-k) 02/09/2016 04:32:07 PM
AMBS News: Statement of Changes in Beneficial Ownership (4) 02/02/2016 10:36:42 AM
AMBS News: Current Report Filing (8-k) 01/29/2016 09:08:11 AM
AMBS News: Current Report Filing (8-k) 01/28/2016 04:24:11 PM
PostSubject
#117775  Sticky Note A leg up on multiple sclerosis (and Alzheimer’s) zoomboom 09/18/15 12:03:13 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#122508   Ambs has same problem as Sunedison(symbol sune, which christjamin 02/12/16 04:57:12 PM
#122507   My faith is based on pipeline. Just received christjamin 02/12/16 04:47:16 PM
#122506   I am not from here. I moved from christjamin 02/12/16 04:43:04 PM
#122505   BTW, are you related to him? Jumpinjackas 02/12/16 04:41:44 PM
#122504   Blind faith is not wisdom. What is your Jumpinjackas 02/12/16 04:41:22 PM
#122503   See anything wrong? No. I have lived worst christjamin 02/12/16 04:40:23 PM
#122502   SCAM-Arantus Bioscience ...... Mmmmmm Zeusgreek7777 02/12/16 04:27:27 PM
#122501   JP Thank you for your post.about the guardiangel 02/12/16 04:15:13 PM
#122499   :) Jumpinjackas 02/12/16 03:45:13 PM
#122497   Wait for it ..... .12 is coming back . Zeusgreek7777 02/12/16 03:34:30 PM
#122496   Just tried to call the CEO. Got Jumpinjackas 02/12/16 03:24:13 PM
#122492   Just buy double after every 60% drop and Slmiley 02/12/16 01:55:13 PM
#122491   You keep buying with every 30%, drop? Do Jumpinjackas 02/12/16 01:51:10 PM
#122488   JC very_smart, great_product_line. GC my CEO. long_GO AMBS GOHAN 02/12/16 01:20:29 PM
#122487   That is 100% correct they can care less Zeusgreek7777 02/12/16 01:20:21 PM
#122486   or as dumb as a box of rocks JPetroInc 02/12/16 01:16:26 PM
#122485   I am long Ambs and am here since christjamin 02/12/16 01:10:19 PM
#122484   OH NO? JPetroInc 02/12/16 01:10:15 PM
#122483   toxics don't want anything to do with the Grundle 02/12/16 01:04:27 PM
#122482   it will be a head fake JPetroInc 02/12/16 01:01:36 PM
#122481   i agree but the problem is the common Grundle 02/12/16 12:54:43 PM
#122480   If he sounds like a con man based Zeusgreek7777 02/12/16 12:54:20 PM
#122479   All buying. No selling right now. christalball 02/12/16 12:50:56 PM
#122477   Question: If this happens to R/S does Dustin Slmiley 02/12/16 12:48:12 PM
#122476   When I took my first job as a Skier1231 02/12/16 12:43:19 PM
#122475   It will be the famous run from .05 Zeusgreek7777 02/12/16 12:36:17 PM
#122474   Yup Jumpinjackas 02/12/16 12:32:53 PM
#122473   Where is the GC chearleading squad today? patience Shadowfaxin 02/12/16 12:32:16 PM
#122472   OTC CEO's do this ! its the Zeusgreek7777 02/12/16 12:26:34 PM
#122471   AMBS should test . 125 again today . Zeusgreek7777 02/12/16 12:22:29 PM
#122470   It fell pretty darn fast . It did Zeusgreek7777 02/12/16 12:20:00 PM
#122469   I guess you're right. christalball 02/12/16 12:18:52 PM
#122468   WOW, talk about a falling knife. Damn. Freeblazer 02/12/16 12:16:44 PM
#122467   he is a devil Alapis 02/12/16 12:14:23 PM
#122466   $0.13 = $0.0008 pre-RS JPetroInc 02/12/16 12:13:15 PM
#122464   As I said before The CEO " ACQUIRED Zeusgreek7777 02/12/16 12:06:06 PM
#122463   new all time low...txs GC Alapis 02/12/16 12:05:14 PM
#122462   People trying to get out of that SCAM Traderbytrade 02/12/16 11:57:09 AM
#122461   CDEX makes a scanner used by law enforcement Skier1231 02/12/16 11:53:36 AM
#122460   Radio silence please. alerted 02/12/16 11:26:14 AM
#122459  Restored JP..you are once again correct in your opinion guardiangel 02/12/16 11:09:07 AM
#122458   AMBS is at extreme risk of a hostile JPetroInc 02/12/16 10:54:15 AM
#122457   GC will reverse split you to death. twogreen2c 02/12/16 10:51:38 AM
#122456  Restored Exit Strategy for Gemini the toxic investor of guardiangel 02/12/16 10:00:19 AM
#122455   Yeah if can't keep the show going it Jumpinjackas 02/12/16 09:39:46 AM
#122454   Am waiting for .12 $AMBS Zeusgreek7777 02/12/16 09:38:46 AM
#122453   Since 2013 ? Wow ! Zeusgreek7777 02/12/16 09:17:10 AM
#122452   Bottom at .16? Conversion price? Jumpinjackas 02/12/16 06:10:11 AM
#122451   Just wait, better moments are already visible around sante1 02/12/16 02:42:57 AM
#122450   Gemini Hedge Fund owned 10% of the Company Skier1231 02/11/16 09:23:15 PM
PostSubject